Physician profile
Christopher M Greene
NPI 1154308740
$16,316.38
in general payments reported to CMS, 2019-2025
50 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,164 · 2020: $1,215 · 2021: $6,252 · 2022: $2,337 · 2023: $1,762 · 2024: $1,423 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,348.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,641.48 | 2020-2025 | |
| Pfizer INC. | $1,266.81 | 2019-2025 | |
| Novo Nordisk INC | $1,030.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $880.30 | 2019-2021 | |
| Amgen INC. | $731.82 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $724.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $715.55 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $707.45 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.16 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $448.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $407.31 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $391.98 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $359.18 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.38 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $269.13 | 2021-2024 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.